Press release
Cirrhosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023
Cirrhosis Pipeline
Key Takeaways from the Cirrhosis Pipeline Report
• DelveInsight's Cirrhosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Cirrhosis treatment.
• The leading companies working in the Cirrhosis Market include GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
• Promising Cirrhosis Pipeline Therapies in the various stages of development include NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
• On August 2023, Grifols Therapeutics LLC announced a study of Phase 3 Clinical Trials for Albutein 20% Injectable Solution. This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites.
• On September 2023, AstraZeneca announced a study of Phase 2 Clinical Trials for zibotentan (dose B) + dapagliflozin. This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Request a sample and discover the recent advances in Cirrhosis Treatment Drugs @ Cirrhosis Pipeline Report- https://www.delveinsight.com/report-store/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Cirrhosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Cirrhosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Cirrhosis clinical trial landscape.
Cirrhosis Overview
Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver damage. The scar tissue prevents the liver working properly. Cirrhosis is sometimes called end-stage liver disease because it happens after other stages of damage from conditions that affect the liver, such as hepatitis.
Find out more about Cirrhosis Treatment Landscape @ Drugs for Cirrhosis Treatment- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cirrhosis Emerging Drugs Profile
• GXHPC 1: GWOXI Stem Cell Applied Technology
• LPCN 1148: Lipocine
• Belapectin: Galectin Therapeutics
Cirrhosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The Cirrhosis companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.
Learn more about the emerging Cirrhosis Pipeline Therapies @ Cirrhosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Cirrhosis Pipeline Report
• Coverage- Global
• Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cirrhosis Companies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
• Cirrhosis Pipeline Therapies- NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
Dive deep into rich insights for new drugs for Cirrhosis Treatment, Visit @ Cirrhosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cirrhosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II/III)
8. Belapectin: Galectin Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GXHPC 1: GWOXI Stem Cell Applied Technology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cirrhosis Key Companies
21. Cirrhosis Key Products
22. Cirrhosis- Unmet Needs
23. Cirrhosis- Market Drivers and Barriers
24. Cirrhosis- Future Perspectives and Conclusion
25. Cirrhosis Analyst Views
26. Cirrhosis Key Companies
27. Appendix
Important Published Links
https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cirrhosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 here
News-ID: 3326645 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Cirrhosis
Cirrhosis Pipeline: Novel Antifibrotic Therapies and Regenerative Approaches Red …
The treatment landscape for cirrhosis, a progressive liver condition marked by fibrosis and compromised liver function, is witnessing a transformative shift as biopharmaceutical companies advance beyond symptomatic management to target the underlying causes of liver damage. With no approved therapies to reverse established fibrosis, there is a growing focus on antifibrotic agents, hepatoprotective compounds, and regenerative therapies that aim to halt or reverse disease progression. Companies like Ocera Therapeutics, Gilead…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known as fibrosis as a result of liver disease damage. Cirrhosis is caused by alcoholic liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B, and chronic hepatitis C.
To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31149
Cirrhosis symptoms emerge slowly until liver…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about Primary Biliary Cirrhosis - Drug Pipeline here: https://www.globalinsightservices.com/reports/primary-biliary-cirrhosis-primary-biliary-cholangitis-drug-pipeline-landscape-2022/
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed…
Liver Cirrhosis - Drug Pipeline Landscape, 2023
New York, Global Insight Services have recently published a report on Liver Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Read more about this report: https://www.globalinsightservices.com/reports/liver-cirrhosis-drug-pipeline-landscape-2023/
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis and end-stage liver disease, is a condition characterised by impaired liver function caused by the formation of scar tissue known…
Primary Biliary Cirrhosis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Primary Biliary Cirrhosis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Primary Biliary Cirrhosis (Primary Biliary Cholangitis) is a chronic disease in which the small bile ducts in the liver become injured and inflamed and are destroyed eventually.
Read more about Primary Biliary Cirrhosis - Drug Pipeline…
Global Liver Cirrhosis Market Growth 2018-2023
Market Research Report Store offers a latest published report on Liver Cirrhosis Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Liver Cirrhosis players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Liver Cirrhosis with respect to individual…
